Navigation Links
Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
Date:2/7/2013

CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf=Astoria in New York City.

Carl Spana , Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs on Monday, February 11, 2013 at 11:00 a.m. ET.

Palatin Technologies has reported positive top-line results in its recently completed Phase 2B clinical trial with bremelanotide for treatment of female sexual dysfunction, and is preparing for an end-of-Phase 2 meeting with the Food and Drug Administration in anticipation of commencing Phase 3 trials. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through February 18, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference i
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
7. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
9. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
10. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
11. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) ... market segments, including the molecular diagnostics industry. BCC Research reveals in its new report ... tests, lower test costs, and a growing need for better diagnostics as part of ...
(Date:7/1/2015)... 2015 Isagenix International, a leading global health ... three Silver, and three Bronze Stevie® Awards at the ... Chicago this month.The American Business ... program in the U.S. "Winning is ... developing leaders, cultivating talent, creating a unified team, and ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Corporation, a company enabling a new generation of molecular ... Mo lecule A rray (SiMoA ™ ) ... measure biomarkers of inflammation from patients with Crohn,s disease. ... was possible using Quanterix,s high sensitivity digital ELISA, allowed ...
... small package. For instance, these tiny cylinders of carbon ... than a metal conductor of the same size. It,s ... future nanoscale electronics. Butnot so fast. Recent tests ... suggest device reliability is a major issue. Copper ...
... CBI is pleased to announce the full agenda for ... being held September 20-22, 2011 in Philadelphia, PA. The ... from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, ... Attendees have the opportunity to customize their congress experience ...
Cached Biology Technology:Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease 2NIST uncovers reliability issues for carbon nanotubes in future electronics 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... implant such as a new hip or pacemaker with nanosized ... the University of Gothenburg, Sweden, can now explain why: they ... the International Journal of Nanomedicine . "Activation of ... common reasons for an implant being rejected," explains Professor Hans ...
... of ageing on the immune system received a boost ... (BBSRC) announced investment in a new 3.6 million research ... from the Babraham Institute with partners from the University ... The team hopes to illuminate a fundamental but little ...
... Livermore National Laboratory Geochemist Tom Guilderson has been ... prestigious Ernest Orlando Lawrence Award, Energy Secretary Steven ... for ground-breaking radiocarbon measurements of corals, advancements in ... processes revealing past climate variability, and the explanation ...
Cached Biology News:Cobblestones fool innate immunity 2New research aims to shed light on how aging affects immunity 2New research aims to shed light on how aging affects immunity 3Geochemist Tom Guilderson wins E.O. Lawrence Award for radiocarbon work 2
FRACTALKINE [Human] (Recombinant)...
... Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps ... ... ... ...
... System with the xPONENT Software Interface ... multi-analyte assays using Upstate's Beadlyte® reagents. ... user friendly xPONENT software developed by ... templates for commercial or home-made multiplex ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Biology Products: